drugset / Trial / NCT06641388

A Study Evaluating the Single Subcutaneous Injection of Ebronucimab in Chinese Healthy Male Subjects

NCT06641388 ↗

Phase 1 Not yet recruiting 180 enrolled Akeso
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a phase I clinical study to evaluate the pharmacokinetics (PK) similarity of single dose subcutaneous injection of Ebronucimab with different production processes in Chinese healthy male subjects.

Timeline

Start
2024-11-04
Primary completion
2025-04-30
Completion
2025-06-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Ebronucimab Unknown 150 mg Subcutaneous

Indications

No indication recorded.